Drugs / rAd35
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00801697 | Feb 2009 → Feb 2011 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAd35 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00801697 ↗ |
| Modality | Vaccine | “recombinant adenoviral serotype 35 (rAd35) and serotype 5 (rAD5) HIV-1 vaccines” NCT00801697 ↗ |
| Route | Intramuscular | “rAd35 intramuscularly at study entry” NCT00801697 ↗ |